[HTML][HTML] Baseline Ad5 serostatus does not predict Ad5 HIV vaccine–induced expansion of adenovirus-specific CD4+ T cells
NA Hutnick, DG Carnathan, SA Dubey, G Makedonas… - Nature medicine, 2009 - nature.com
NA Hutnick, DG Carnathan, SA Dubey, G Makedonas, KS Cox, L Kierstead, SJ Ratcliffe…
Nature medicine, 2009•nature.comThe mechanisms underlying possible increased HIV-1 acquisition in adenovirus 5 (Ad5)-
seropositive subjects vaccinated with Ad5–HIV-1 vectors in the Merck STEP trial remain
unclear. We find that Ad5 serostatus does not predict Ad5-specific CD4+ T cell frequency,
and we did not observe durable significant differences in Ad5-specific CD4+ T cells between
Ad5-seropositive and Ad5-seronegative subjects after vaccination. These findings indicate
no causative role for Ad5-specific CD4+ T cells in increasing HIV-1 susceptibility in the STEP …
seropositive subjects vaccinated with Ad5–HIV-1 vectors in the Merck STEP trial remain
unclear. We find that Ad5 serostatus does not predict Ad5-specific CD4+ T cell frequency,
and we did not observe durable significant differences in Ad5-specific CD4+ T cells between
Ad5-seropositive and Ad5-seronegative subjects after vaccination. These findings indicate
no causative role for Ad5-specific CD4+ T cells in increasing HIV-1 susceptibility in the STEP …
Abstract
The mechanisms underlying possible increased HIV-1 acquisition in adenovirus 5 (Ad5)-seropositive subjects vaccinated with Ad5–HIV-1 vectors in the Merck STEP trial remain unclear. We find that Ad5 serostatus does not predict Ad5-specific CD4+ T cell frequency, and we did not observe durable significant differences in Ad5-specific CD4+ T cells between Ad5-seropositive and Ad5-seronegative subjects after vaccination. These findings indicate no causative role for Ad5-specific CD4+ T cells in increasing HIV-1 susceptibility in the STEP trial.
nature.com